Orphan diseases pose both a challenge to the global medical community and an opportunity for it to focus on global peace engineering and innovation. Where, any single orphan disease is rare, when taken as a whole they affect more than 250 million people throughout the world. This number by comparison is larger than the global number of cancer and AIDS patients. We add to the literature by mapping the available knowledge in the orphan drug development field and exploring the tensions at play for innovation and entrepreneurship in this field. We further add to the literature by providing a framework to review this field based on social systems theory. Our review highlights the gaps in research and proposes a path forward in understanding of a...
In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more than 7,0...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
ABSTRACTWe argue that orphan drug policies have been useful in incentivizing socially desirable R&D ...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
This paper surrounds innovation as socially constructed and posits a model for innovation policy ba...
Rare diseases have a prevalence of lower than 5 in 10,000 inhabitants and are life-threatening or ch...
Rare diseases are associated with difficulties in addressing unmet medical needs, lack of access to ...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatmen...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
Rare diseases remain a challenge for many of the countries in the world. The millions of people coll...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more than 7,0...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
ABSTRACTWe argue that orphan drug policies have been useful in incentivizing socially desirable R&D ...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
This paper surrounds innovation as socially constructed and posits a model for innovation policy ba...
Rare diseases have a prevalence of lower than 5 in 10,000 inhabitants and are life-threatening or ch...
Rare diseases are associated with difficulties in addressing unmet medical needs, lack of access to ...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatmen...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
Rare diseases remain a challenge for many of the countries in the world. The millions of people coll...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more than 7,0...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
ABSTRACTWe argue that orphan drug policies have been useful in incentivizing socially desirable R&D ...